Common Stock, par value $0.00033 per share
- Symbol
- PDSB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
PDS Biotechnology Corporation
PDSBNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On October 6, 2026, PDS Biotechnology Corporation issued a press release announcing that the company will host a virtual key opinion leader (KOL) event featuring Jonathan M. Hernandez, M.D, an investigator with the Surgical Oncology Program at the National Cancer Institute’s Center for Cancer Research. Dr.…
Company context
We are a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our Versamune® T cell activator and Versamune® in combination with our interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC. In addition, we are developing the Infectimune® T cell-activator in infectious diseases.
Current securities
Recent company filings
- Other EventsSep 22, 2026
- SCHEDULE 13D - filed by Nant Capital, LLC regarding PDS Biotechnology CorpSep 21, 2026
- Other EventsSep 21, 2026
- Termination of a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure · Other EventsSep 14, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD DisclosureSep 8, 2026
Registered securities in this filing
PDS BIOTECHNOLOGY CORPORATION · 8-K · Filed 2026-10-06
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On October 6, 2026, PDS Biotechnology Corporation issued a press
release announcing that the company will host a virtual key opinion leader (KOL) event featuring Jonathan M. Hernandez, M.D, an investigator with the Surgical Oncology Program
at the National Cancer Institute’s Center for Cancer Research. Dr. Hernandez will join company management to discuss clinical outcomes from the PDS0301 Phase 2 trials for the treatment of advanced liver-associated cancers, with a focus on the
metastatic colorectal cancer (mCRC) cohort.
A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.
Filed exhibits (1)
Exhibit 99.1 PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases Virtual Event Featuring Jonathan M. Hernandez, M.D, Investigator, Surgical Oncology Program, NCI/CCR, to Be Held October 15, 2026, at 8am ET PRINCETON, N.J., October 6, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a virtual key opinion leader (KOL) event featuring Jonathan M. Hernandez, M.D, an Investigator with Surgical Oncology Program at the National Cancer Institute’s Center for Cancer Research. Dr. Hernandez will join company management to discuss clinical outcomes from the PDS0301 Phase 2 trials for the treatment of advanced liver-associated cancers, with a focus on the metastatic colorectal cancer (mCRC) cohort. The event will provide an overview of the PDS0301 trial in patients with second and third line unresectable microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal liver metastases. These MSS patients constitute the ma…
Open exhibit ↗